Ferraris sells respiratory division to nSpire Health
This article was originally published in Clinica
Ferraris has completed the sale to private investors of its loss-making respiratory division for $3.9m. The Birmingham, UK-based firm, which in July sold its cardiac business, Del Mar Reynolds Medical, for £14m ($27m), is narrowing its focus to in vitro diagnostics control solutions and X-ray crystallography cryosystems only.
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.